奥氮平治疗老年躯体疾病所致精神障碍疗效

Efficacy of Olanzapine in the Treatment of Mental Disorders Caused by Somatic Diseases in the Elderly

目的探讨不同剂量的奥氮平治疗老年躯体疾病所致精神障碍的临床疗效和不良反应发生情况。方法收集我院2017年1月—2018年12月的老年躯体疾病所致的精神障碍患者共80例,分为对照组和观察组各40例,两组患者针对躯体疾病进行对症治疗,对照组采用15~20mg奥氮平片治疗,观察组采用5~10mg奥氮平片治疗,两组患者各治疗8周。观察临床疗效和不良反应。结果对照组和观察组的治疗总有效率分别为77.50%和82.50%,两组患者治疗后的临床有效率对比无显著差异(P>0.05)。两组患者治疗前的阳性和阴性症状量表(Positive and Negative Syndrome Scale,PANSS)、日常生活能力量表(Activity Daily Living Scale,ADL)、简明精神病量表(Brief psychiatric rating scale,BPRS)评分对比差异无统计学意义(P>0.05),治疗后两组患者的PANSS、BPRS评分较治疗前出现下降,ADL评分较治疗前出现上升(P<0.05),两组患者治疗后的PANSS、ADL、BPRS评分对比差异无统计学意义(P>0.05),对照组和观察组的不良反应发生率分别为22.50%和5.00%,观察组不良反应发生率低于对照组,对比差异具有统计学意义(P<0.05)。结论不同剂量的奥氮平治疗老年躯体疾病所致精神障碍的临床疗效相当,小剂量治疗的不良反应发生率较低,安全性较高。

Objective To investigate the clinical efficacy and adverse reactions of different doses of olanzapine in the treatment of mental disorders caused by somatic diseases in the elderly. Methods A total of 80 patients with mental disorders caused by somatic diseases from January 2017 to December 2018 in our hospital were enrolled, and 40 patients in the control group and the observation group were enrolled. The two groups were treated symptomatically for physical diseases. The control group was treated with 15~20 mg olanzapine tablets, and the observation group was treated with 5~10 mg olanzapine tablets. The two groups were treated for 8 weeks each. Observe clinical efficacy and adverse reactions. Results The total effective rate of the control group and the observation group were 77.50% and 82.50%, respectively. There was no significant difference in the clinical effective rate between the two groups (P > 0.05). There was no statistical significance differences between the two groups of patients before treatment with Positive and Negative Syndrome Scale (PANSS), Activity Daily Living Scale (ADL), and Brief Psychiatric Rating Scale (BPRS) scores (P > 0.05). After treatment, the PANSS and BPRS scores of the two groups were lower than those before treatment, and the ADL scores were higher than those before treatment (P < 0.05). PANSS, ADL and BPRS after treatment in the two groups, there was no significant difference in scores between the two groups (P > 0.05). The incidence of adverse reactions in the control group and the observation group were 22.50% and 5.00%, respectively. The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion Different doses of olanzapine are effective in the treatment of mental disorders caused by somatic diseases in the elderly. The incidence of adverse reactions in low-dose treatment is lower and the safety is higher.